Skip to content
Peptide Science Journal
Structural & Mechanism

BPC-157: A Complete Research Overview

BPC-157 — short for body protection compound 157, a pentadecapeptide first isolated from a fragment of human gastric juice protein — is one of the most-studied research peptides of the last twenty years. The published animal-study literature is unusually deep for a research compound that has not yet completed Phase II human trials, and the mechanisms proposed for its activity sit at the intersection of angiogenesis, growth-factor receptor signaling, and nitric-oxide biology that the broader regenerative-medicine field cares about for unrelated reasons.

This overview summarizes what the peer-reviewed literature has established about BPC-157 in research contexts: its origin, structure, the mechanisms repeatedly proposed in animal studies, the categories of preclinical findings that have been reported, the current state of human investigation, and the quality-control considerations any researcher should weight before committing the compound to an experimental design. BPC-157 is described here strictly as a research compound for in vitro and animal-study use. Nothing in this article should be read as a recommendation for human use, a dosing recommendation, or a therapeutic claim.

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The molecule was first characterized in the early 1990s by the Croatian gastroenterology group led by Predrag Sikiric, who isolated and synthesized it from a larger gastric protective protein found in human gastric juice. The “157” designation refers to its position in the parent protein sequence.

Reference identifiers commonly cited on a Certificate of Analysis:

  • CAS Registry Number: 137525-51-0
  • Molecular formula: C₆₂H₉₈N₁₆O₂₂
  • Molecular weight: ~1419.53 g/mol
  • Sequence: GEPPPGKPADDAGLV

These values should appear on every BPC-157 CoA from a quality vendor. A researcher purchasing BPC-157 should verify the molecular weight on the published mass spectrum against the theoretical value, with an acceptable mass-accuracy window typically within ±0.5 Da of the [M+H]⁺ ion. A quality vendor publishes the CoA for every BPC-157 lot; the lot number on the vial should resolve to the corresponding PDF.

Mechanisms proposed in the literature

The most thoroughly reviewed mechanism for BPC-157’s regenerative effects in animal studies involves modulation of angiogenesis through the vascular endothelial growth factor receptor 2 (VEGFR2) pathway. In a 2016 paper published in the Journal of Molecular Medicine, Hsieh and colleagues demonstrated that BPC-157 administration upregulated VEGFR2 expression in rats with hind limb ischemia and in endothelial cell culture, and promoted VEGFR2 internalization in association with downstream Akt-eNOS activation [Hsieh et al., 2017, PMID 27847966; DOI 10.1007/s00109-016-1488-y]. The same study reported increased vessel density both in vivo and in vitro and accelerated recovery of blood flow in the ischemic limb, as measured by laser Doppler scanning. Whether the VEGFR2 effect is a direct receptor interaction or a downstream consequence of upstream nitric-oxide signaling remains under debate in the literature.

The nitric-oxide axis is the second pillar of the proposed mechanism. Multiple papers from the Sikiric group and independent investigators have reported that BPC-157 effects can be modulated by L-NAME (a nitric oxide synthase inhibitor) and L-arginine (an NO precursor), consistent with the peptide acting at least partly through endothelial nitric oxide synthase (eNOS) activation [Sikiric et al., 2018, narrative review; Sikiric et al., 2024 follow-up commentary, MDPI Pharmaceuticals 18, 1450]. The mechanistic picture that has emerged is one of overlapping pathways: VEGFR2 upregulation, Akt phosphorylation, eNOS activation, increased local NO availability, increased angiogenesis, and accelerated wound-bed perfusion — all of which would be expected to support tissue repair in a wide range of injury models.

A third mechanism reported in the literature involves the growth hormone receptor (GHR). In a 2018 paper in the International Journal of Molecular Sciences, Chang and colleagues demonstrated that BPC-157 enhanced growth hormone receptor expression in tendon fibroblasts, with concomitant upregulation of downstream proliferative and collagen-synthetic gene expression [Chang et al., 2018, PMID 30463375; PMC6271067]. The GHR upregulation is mechanistically distinct from the VEGFR2/eNOS axis and may explain BPC-157’s particular activity in tendon and ligament models, where fibroblast proliferation and Type I collagen deposition are rate-limiting.

A 2025 narrative review in MDPI Pharmaceuticals by Jozwiak et al. summarized the broader literature, cataloguing reported activity across gastrointestinal mucosal protection, central nervous system models, vascular protection, and musculoskeletal repair [Jozwiak et al., 2025, MDPI Pharmaceuticals 18, 185; DOI 10.3390/ph18020185]. The 2025 review and the Sikiric group’s 2025 response commentary together provide the most current literature snapshot.

Categories of animal-study findings

The reported preclinical findings cluster into several categories. The following summarizes what has appeared in peer-reviewed publications. None of this constitutes evidence of safety or efficacy in humans, and none of it should be read as a recommendation for human use.

Gastrointestinal mucosal models

The original research direction. Multiple animal studies have reported that BPC-157, administered orally or parenterally, accelerated healing of induced gastric mucosal lesions in animal models, reduced lesion size and severity, and maintained mucosal integrity under conditions (NSAID exposure, ethanol exposure, stress) that normally produced significant tissue damage [Sikiric et al., 1993 onward, summarized in the 2025 Jozwiak review].

Musculoskeletal repair models

The largest category of BPC-157 literature. Animal studies of severed muscle-tendon injury have reported that BPC-157 treatment was associated with restored structural integrity and biomechanical function in the affected unit, with histological evidence of organized tissue architecture at the repair site. Similar findings have been reported in models of Achilles tendon transection, medial collateral ligament transection, and bone-defect healing, with reported acceleration of repair timelines and improvements in measured biomechanical strength.

A 2025 systematic review published in the Journal of Hip and Knee Surgery by Vasireddi and colleagues examined the published BPC-157 musculoskeletal literature through 2024 and noted the breadth of preclinical findings while emphasizing the absence of completed human trials in orthopedic indications [Vasireddi et al., 2025, DOI 10.1177/15563316251355551]. A separate 2025 narrative review by independent authors in PubMed (PMID 40789979) framed the same body of work as “regeneration or risk” — emphasizing both the strength of preclinical signals and the gap to human evidence.

Central nervous system models

A smaller body of work has reported BPC-157 effects in animal models of central nervous system injury, including reported effects in models of traumatic brain injury, spinal cord injury, and cuprizone-induced demyelination. The proposed mechanisms in these contexts overlap with those described above — VEGFR2-mediated angiogenesis, NO-mediated vascular protection — and are reviewed in the 2025 Jozwiak summary.

Anti-inflammatory and antioxidative findings

Across most of the BPC-157 literature, animal-study readouts have included reduced inflammatory-cell infiltration, normalized oxidative-stress markers (MDA, GSH), and reduced pro-inflammatory cytokine expression in healing tissues. Whether these are primary effects or downstream consequences of accelerated tissue repair is mechanistically ambiguous in most of the published designs.

Current state of human investigation

Human data on BPC-157 remain extremely limited. Per the 2025 systematic reviews, only a small number of pilot human studies have been published, including a knee-osteoarthritis intraarticular pilot, an interstitial-cystitis pilot, and a Phase I-style intravenous pharmacokinetics study. No completed Phase II or Phase III trial has been published as of the date of this article.

BPC-157 was placed on the FDA’s “compounding 503A bulks list — Category 2” (insufficient information to evaluate) in late 2023 and is currently scheduled to be re-evaluated by the FDA Pharmacy Compounding Advisory Committee at its July 23–24, 2026 meeting. The outcome of that re-evaluation will affect the regulatory status of compounded BPC-157 products in the United States. None of this status applies to BPC-157 sold as a research compound; the regulatory framework for RUO chemistry is separate and the existing class of research compounds remains available for in vitro and animal-study use.

What researchers should look for in a BPC-157 CoA

Before committing BPC-157 to an experimental design, the published CoA on the lot should be reviewed. The minimum data set:

  • HPLC purity ≥ 99.0% by area, with the chromatogram visible. Minor peaks should be characterized; large unidentified impurity peaks are disqualifying.
  • Mass spectrometry confirmation of the expected [M+H]⁺ at ~1420.53, observed within ±0.5 Da of theoretical.
  • Amino acid analysis or sequence confirmation, where available.
  • Net peptide content (often distinguished from gross mass — for a lyophilized vial labeled “10 mg,” the net peptide content may be 85–95% of the gross, with the balance being counterion salts and residual moisture). The CoA should report the net.
  • Endotoxin levels for any work that requires it (cell culture, animal study). Not always reported on baseline CoAs; ask the vendor.
  • Lot number and manufacturing date. Lot traceability is non-negotiable for reproducible research.

A quality vendor publishes the full CoA for every BPC-157 lot; the lot number on the vial label should resolve to the corresponding PDF, and researchers should verify the CoA before reconstitution.

For a deeper guide to reading a peptide CoA — including what each peak in the HPLC chromatogram represents and how to validate the mass spectrum — see the companion guide, “How to Read a Peptide Certificate of Analysis”.

Storage and handling in a research setting

Lyophilized BPC-157 is stable for an extended period when stored properly. The general protocol for research peptides:

  • Lyophilized (unreconstituted): store at room temperature, away from light. Refrigeration is not required for the lyophilized form for typical study timeframes (months). For multi-year storage, freezer storage at -20°C in a low-humidity environment extends shelf life.
  • Reconstituted: refrigerate at 2–8°C immediately after reconstitution. Use within 28 days. Standard reconstitution medium for research peptides is bacteriostatic water (0.9% benzyl alcohol), which provides the multi-dose stability that makes 28-day use windows possible.

Reconstitution best practices: add bacteriostatic water slowly down the inside wall of the vial. Do not shake. Gentle swirling or inverting only — vigorous agitation generates air-liquid interfaces that can denature the peptide. Allow several minutes for complete dissolution.

For more on the lyophilized-vs-reconstituted stability tradeoff and the underlying chemistry, see the companion guide, “Lyophilized vs. Reconstituted Peptides: A Storage Protocol Guide”.

Limitations of the BPC-157 literature

A fair summary requires acknowledging the gaps:

  • Single-group dominance. A meaningful share of the published BPC-157 literature originates from the Sikiric group at the University of Zagreb. Replication by independent groups exists but is less extensive than for compounds with broader investigator interest. The reproducibility of certain reported findings has been debated in correspondence published in MDPI Pharmaceuticals in 2025.
  • Mechanism not fully resolved. The VEGFR2 / Akt / eNOS axis is the leading mechanistic hypothesis, but the receptor that BPC-157 binds to initiate signaling has not been definitively identified. Whether BPC-157 binds directly to VEGFR2, to a related receptor, or acts upstream through an unknown intermediary remains an open question.
  • Pharmacokinetics in animal models. BPC-157’s reported activity after oral administration in animal studies is notable for a peptide that would be expected to be degraded in the gastric environment. The mechanism of oral bioavailability — and whether reported oral effects are mediated by an intact peptide or by a degradation product — has not been resolved.
  • Translation to human data. Animal-model findings have not yet been validated by adequately-powered controlled trials in humans. The translation gap is the standard situation for a research compound at this maturity level.

These limitations are not arguments against further research; they are the reason further research is being conducted.

How BPC-157 sits in the broader peptide research catalog

In a research catalog, BPC-157 is most often grouped with other compounds investigated for tissue-repair and musculoskeletal-repair contexts in animal models — including thymosin beta-4 (TB-500), the BPC-157 + TB-500 blend, KPV, and LL-37. Each compound has its own mechanism and its own literature; they appear in similar research contexts because they are studied in overlapping injury models.

Summary

BPC-157 is a pentadecapeptide isolated from a fragment of human gastric juice protein, characterized in the early 1990s, with an unusually deep peer-reviewed animal-study literature reporting effects in models of mucosal protection, musculoskeletal repair, central nervous system injury, and inflammation. The leading mechanistic hypothesis is VEGFR2/Akt/eNOS-mediated angiogenesis with parallel growth-hormone-receptor effects on fibroblast proliferation. Human data are limited to a small number of pilot studies. The compound is currently scheduled for FDA Pharmacy Compounding Advisory Committee re-evaluation in July 2026, separate from its status as a research compound for in vitro and animal-study use.

Researchers ordering BPC-157 should verify the CoA — HPLC purity, mass spectrometry confirmation, net peptide content, lot traceability — before use, and should follow standard lyophilized-peptide storage and reconstitution protocols.

Selected peer-reviewed sources

  1. Hsieh M-J, et al. “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.” Journal of Molecular Medicine (2017). PMID 27847966. https://link.springer.com/article/10.1007/s00109-016-1488-y
  2. Chang C-H, et al. “Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts.” PMC6271067. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271067/
  3. Jozwiak M, et al. “Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review.” Pharmaceuticals (2025) 18, 185. DOI 10.3390/ph18020185. https://www.mdpi.com/1424-8247/18/2/185
  4. Sikiric P, et al. “BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions.” Pharmaceuticals (2025) 18, 1450. https://www.mdpi.com/1424-8247/18/10/1450
  5. Vasireddi N, et al. “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.” (2025). DOI 10.1177/15563316251355551. https://journals.sagepub.com/doi/abs/10.1177/15563316251355551
  6. Krivic A, et al. “Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing.” PMID 20388964. https://pubmed.ncbi.nlm.nih.gov/20388964/
  7. “From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.” MDPI International Journal of Molecular Sciences (2025). https://www.mdpi.com/1422-0067/27/6/2876
  8. “Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.” PMID 40789979. https://pubmed.ncbi.nlm.nih.gov/40789979/

Research Use Only — Disclaimer

BPC-157 is described here for laboratory and research purposes only. The compound is intended exclusively for in vitro experimentation and for use in animal studies under appropriate institutional oversight. It is not a drug, dietary supplement, cosmetic, or food additive. It is not for human consumption, not for veterinary use in companion animals, and not for any therapeutic, diagnostic, preventive, or palliative purpose.

Nothing on this page constitutes medical advice. No statement on this page should be interpreted as a recommendation, claim, or representation that BPC-157 is safe, effective, or appropriate for any use in humans. Animal-study findings reported in the peer-reviewed literature are described for research context only and do not establish safety or efficacy in any species, including humans. Researchers must comply with all applicable laws, institutional review requirements, and biosafety protocols.

Buyers must be at least 21 years of age and must agree to use the product strictly for research purposes.